Clinical trial
Capecitabine in Treating Patients With Malignant Mesothelioma
NCT00004183 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00004183 |
|---|---|
| Title | Capecitabine in Treating Patients With Malignant Mesothelioma |
| Official title | Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | capecitabine |
| Enrollment | 27 |
| Start date | Nov 1, 2000 |
| Primary completion | Dec 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Feb 25, 2004 |
| Last update posted | Jul 14, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: